Cocaine Use Disorder: Clinical Trials

18 trials for Cocaine Use Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 18 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 218Completed 10, Recruiting 3, Active not recruiting 2, Terminated 2, Unknown 1
Phase 12Completed 2

Follow Cocaine Use Disorder: new trials by email Literature Review of Cocaine Use Disorder trials Research Report on Cocaine Use Disorder

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder
Tirzepatide - Obesity, Methamphetamine Use Disorder
Phase 2Active not recruitingUniversity of Texas Southwestern Medical Center452026-08-192026-10-29
Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder
Sustained-release Dexamphetamine, Placebo - Cocaine Use Disorder
Phase 2RecruitingParnassia Addiction Research Centre2042026-04-222026-05-29
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder
Semaglutide, Placebo, cognitive behavioral therapy (CBT). - Cocaine Use Disorder
Phase 2RecruitingThe University of Texas Health Science Center, Houston752026-01-152026-03-19
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
Semaglutide, Placebo - Cocaine Use Disorder, HIV
Phase 2Active not recruitingUniversity of Maryland, Baltimore402025-08-072026-09-10
Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction
Ketamine, Placebo, real-time fMRI neurofeedback training - Cocaine Use Disorder, Cocaine Dependence
Phase 2RecruitingDr. med. Marcus Herdener1202024-02-052024-12-20
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks, CBOT Sham - Substance Use Disorders, Opioid Use Disorder
Phase 2UnknownEvon Medics LLC3002023-07-072024-05-30
Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
Extended-Release Naltrexone, Extended Release Buprenorphine, Placebo (PLB) Injectable matched to XR-NTX - Cocaine Use Disorder
Phase 2CompletedUniversity of Texas Southwestern Medical Center4272023-04-182025-10-21
Cariprazine for Comorbid Cocaine and Opioid Use Disorder
Cariprazine 1.5 MG, Placebo - Opioid-use Disorder, Cocaine Use Disorder
Phase 2CompletedKyle Kampman262022-08-052026-01-23
Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention
Cognitive Behavioral Therapy (CBT), Pioglitazone, Placebo - Cocaine Use Disorder
Phase 2CompletedThe University of Texas Health Science Center, Houston612021-08-232026-09-21
Exenatide for Treating Cocaine Use Disorder
Exenatide 2 mg [Bydureon], Drug Counseling - Cocaine Use Disorder
Phase 1 / Phase 2CompletedThe University of Texas Health Science Center, Houston32021-06-242022-06-27
TDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
transcranial direct current stimulator (tDCS), Cognitive Reappraisal - Cocaine Use Disorder, Cocaine Dependence
Phase 2CompletedSoterix Medical602020-09-282024-11-18
A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
EMB-001, EMB-001 Placebo - Cocaine Use Disorder
Phase 2CompletedEmbera NeuroTherapeutics, Inc.822020-07-292026-09-21
Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder
Cariprazine Oral Capsule [Vraylar], Placebo oral capsule - Cocaine Use Disorder
Phase 2TerminatedAnna Rose Childress, Ph.D.142018-04-042020-09-09
Treatment With Lorcaserin for Cocaine Use: The TLC Study
lorcaserin, Placebo Oral Tablet, Substance use counseling - Cocaine Use Disorder
Phase 2TerminatedGlenn-Milo Santos222018-01-012023-08-14
Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use
suvorexant, Placebo (for suvorexant) - Cocaine Use Disorder, Anxiety
Phase 2CompletedThe University of Texas Health Science Center, Houston202016-05-012019-12-11
Trial Of NS2359 For The Treatment of Cocaine Dependence
NS2359, placebo - Cocaine Use Disorder
Phase 2CompletedUniversity of Pennsylvania552016-05-012021-05-24
Neural Substrates of Emotion: Impact of Cocaine Dependence
Oxytocin, Placebo - Cocaine Use Disorder
Phase 2CompletedMedical University of South Carolina1382015-07-012021-10-21
PPARγ Agonist Treatment for Cocaine Dependence
Pioglitazone, Placebo, Therapy - Cocaine Use Disorder, Alcohol Use Disorder
Phase 1 / Phase 2CompletedThe University of Texas Health Science Center, Houston302012-08-012018-04-26

Narrower conditions

Cocaine-Related Disorders (5)  ·  Opioid-Related Disorders (3)  ·  Alcoholism (2)  ·  Anxiety Disorders (1)  ·  Behavior, Addictive (1)  ·  Obesity (1)  ·  Overweight (1)  ·  Recurrence (1)  ·  Sexual Behavior (1)  ·  Substance-Related Disorders (1)

Broader conditions

Mental Disorders (10)  ·  Chemically-Induced Disorders (9)  ·  Substance-Related Disorders (8)  ·  Narcotic-Related Disorders (3)  ·  Alcohol-Related Disorders (2)  ·  Behavior (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Body Weight (1)  ·  Compulsive Behavior (1)  ·  Disease Attributes (1)  ·  Impulsive Behavior (1)  ·  Nutrition Disorders (1)  ·  Nutritional and Metabolic Diseases (1)  ·  Overnutrition (1)  ·  Pathologic Processes (1)

Interventions

Starch (3)  ·  Cognitive Behavioral Therapy (2)  ·  Pioglitazone (2)  ·  cariprazine (2)  ·  semaglutide (2)  ·  Ecological Momentary Assessment (1)  ·  Exenatide (1)  ·  GSK372475 (1)  ·  Ketamine (1)  ·  Oxytocin (1)  ·  Saline Solution (1)  ·  Therapeutics (1)  ·  Tirzepatide (1)  ·  lorcaserin (1)  ·  phospholamban (1)

Sponsors

The University of Texas Health Science Center, Houston (5)  ·  University of Texas Southwestern Medical Center (2)  ·  Anna Rose Childress, Ph.D. (1)  ·  Dr. med. Marcus Herdener (1)  ·  Embera NeuroTherapeutics, Inc. (1)  ·  Evon Medics LLC (1)  ·  Glenn-Milo Santos (1)  ·  Kyle Kampman (1)  ·  Medical University of South Carolina (1)  ·  Parnassia Addiction Research Centre (1)  ·  Soterix Medical (1)  ·  University of Maryland, Baltimore (1)  ·  University of Pennsylvania (1)

Countries

United States (16)  ·  Netherlands (1)  ·  Switzerland (1)

Top investigators

Joy M Schmitz, PhD (2)  ·  Luba Yammine, PhD (2)  ·  Abhishek Datta, PhD (1)  ·  Aimee L McRae-Clark, PharmD (1)  ·  Anna Rose Childress, PhD (1)  ·  Bruce McCarthy, MD (1)  ·  Charles Nwaokobia (1)  ·  Edwin Chapman, MD (1)  ·  Evaristus Nwulia, MD (1)  ·  Glenn-Milo Santos, PhD, MPH (1)  ·  Joy Schmitz, PhD (1)  ·  Madhukar Trivedi, MD (1)  ·  Manish Jha, M.B.B.S. (1)  ·  Marc Fishman, MD (1)  ·  Scott D Lane, PhD (1)

Results publications

PMID 34265007, PMID 37579116, PMID 40360074, PMID 40999531, PMID 42161545

NIH funding

P50DA009262 (1), R01DA048026 (1), R01DA062720 (1), R34DA042161 (1), R44DA056156 (1), U01DA038879 (1), UG1DA020024 (1)